SYVN1 and Obesity: HRD1 appears to be a potential therapeutic target for HFD-induced obesity and fatty liver disease, because the induced deletion of HRD1 genes even after 6 weeks of a HFD prevented further body weight gain, largely diminished evidence of fatty liver disease, and abolished insulin resistance in mice.